Global Trial Marks Advance for a Hard-to-Treat Blood Cancer

Essential thrombocythemia (ET) is a rare blood cancer in which abnormal stem cells in the bone marrow churn out too many platelets, raising the risk of dangerous clots, strokes and heart attacks, and in some cases progressing to more serious cancers. For high-risk patients, the standard treatment is hydroxyurea — but about a third of them eventually become intolerant or stop responding, leaving doctors short of good options. A recently published global trial offers an encouraging new path.

The study, known as SURPASS-ET, was led by Wake Forest University School of Medicine and Atrium Health Levine Cancer, and its findings were recently published in The Lancet Haematology. It enrolled nearly 175 patients across more than 50 clinical sites in Asia and North America, comparing the drug ropeginterferon alfa-2b against anagrelide in people who could no longer use hydroxyurea.

The results favored the newer therapy. Patients treated with ropeginterferon alfa-2b had better control of their platelet counts, fewer symptoms and fewer serious problems than those on anagrelide. “This represents a major treatment advance for these tough-to-treat patients,” the researchers noted, with principal investigator Dr. Ruben Mesa leading the international effort. Because the disease can quietly raise the risk of life-threatening clots for years, better long-term control matters a great deal for patients’ quality of life and safety.

As with any single trial, context is important. The number of participants was modest, reflecting how rare ET is, and longer follow-up will help confirm the durability of the benefit and the full safety profile. Regulators were still reviewing an application to expand the drug’s approved use, with a decision expected later in 2026. Even so, for patients who had run out of standard choices, a therapy shown to control the disease better and more comfortably is a genuinely hopeful development.